Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Bridge Biotherapeutics Joins PROLIFIC, the Prognostic Lung Fibrosis Consortium 2023-07-12 06:00
Putting Patients First: The Quest to Make Anticancer Cell Therapy Accessible to All 2023-07-12 06:00
DISCOVERY LIFE SCIENCES ACCELERATES CLINICAL TRIALS WITH ADDITION OF FULL-SPECTRUM CLINICAL FLOW CYTOMETRY 2023-07-11 20:05
Doer Biologics Announces License Agreement with BioNTech 2023-07-11 11:49
Race executes global license agreement with City of Hope to access FTO IP 2023-07-11 07:30
Quest PharmaTech Provides Product Development Update 2023-07-11 04:30
TCI Introduces VeCollal®, the Biomimetic Collagen Most Identical to Human Collagen from Belgium Validated by Human Clinical Study. 2023-07-10 20:21
Race executes global license agreement with City of Hope to access FTO IP 2023-07-10 19:30
Patsnap: Supercharging FTO Search with Degenerate Sequence Searching 2023-07-10 18:24
BRONCUS COMPLETES THE FIRST CASE OF REGISTERED CLINICAL TRIALS OF ITS TARGETED LUNG DENERVATION RADIOFREQUENCY ABLATION SYSTEM 2023-07-10 12:56
RemeGen and Innovent Collaborate on Clinical Trials to Evaluate the Potential of RC88 and RC108 Combined with PD-1 Therapy for Advanced Solid Tumors 2023-07-10 10:24
280 Bio receives IND approval from the FDA for YL-17231 2023-07-07 20:00
Kexing Biopharm Makes it into China's Top 20 Biopharmaceutical Enterprises (Blood Products, Vaccines and Insulin) for Two Consecutive Years 2023-07-07 19:43
Transcenta Received Approvals from China CDE and South Korea MFDS to Initiate TranStar 301 Global Phase III Pivotal Trial of Osemitamab (TST001) 2023-07-07 15:52
Forge Stronger Partnership for Advanced ADC Development! GeneQuantum Healthcare and Aimed Bio collaborate to develop five innovative ADC drugs 2023-07-07 10:19
Hexvix®, A Diagnostic Drug for Bladder Cancer of Asieris has Completed the Phase III bridging trial Enrollment 2023-07-06 18:33
Genesis MedTech Receives Approval for Launch in China for ArtiSential™ 2023-07-06 18:00
Registrational Pivotal Phase III Study of Olverembatinib for the First-Line Treatment of Patients with Ph+ ALL Approved by the CDE in China 2023-07-06 10:38
MGI's DNBSEQ-T7* Receives Approval for Clinical Use in South Korea 2023-07-06 09:00
Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Cure 2023-07-06 07:25
1 94 95 96 97 98 452